Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cara Therapeutics, Inc. (CARA : NSDQ)
 
 • Company Description   
Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.

Number of Employees: 84

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.68 Daily Weekly Monthly
20 Day Moving Average: 951,745 shares
Shares Outstanding: 53.59 (millions)
Market Capitalization: $465.17 (millions)
Beta: 1.22
52 Week High: $18.93
52 Week Low: $7.40
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.06% -22.36%
12 Week -14.48% -5.99%
Year To Date -28.74% -14.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
107 ELM STREET 9TH FLOOR
-
STAMFORD,CT 06902
USA
ph: 203-406-3700
fax: 203-567-1510
janhavi.mohite@sternir.com http://www.caratherapeutics.com
 
 • General Corporate Information   
Officers
Christopher Posner - Chief Executive Officer and President
Thomas Reilly - Chief Financial Officer
Martin Vogelbaum - Director
Harrison M. Bains - Director
Jeffrey Ives - Director

Peer Information
Cara Therapeutics, Inc. (CORR.)
Cara Therapeutics, Inc. (RSPI)
Cara Therapeutics, Inc. (CGXP)
Cara Therapeutics, Inc. (BGEN)
Cara Therapeutics, Inc. (GTBP)
Cara Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 140755109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 53.59
Most Recent Split Date: (:1)
Beta: 1.22
Market Capitalization: $465.17 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.24 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.28
Price/Cash Flow: -
Price / Sales: 3.61
EPS Growth
vs. Year Ago Period: -10.64%
vs. Previous Quarter: 17.46%
Sales Growth
vs. Year Ago Period: 147.55%
vs. Previous Quarter: 483.43%
ROE
03/31/22 - -44.11
12/31/21 - -40.73
09/30/21 - 10.72
ROA
03/31/22 - -40.50
12/31/21 - -37.48
09/30/21 - 9.86
Current Ratio
03/31/22 - 8.29
12/31/21 - 9.84
09/30/21 - 11.05
Quick Ratio
03/31/22 - 8.19
12/31/21 - 9.69
09/30/21 - 11.04
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -358.88
12/31/21 - -384.06
09/30/21 - 17.57
Book Value
03/31/22 - 3.81
12/31/21 - 4.25
09/30/21 - 4.14
Inventory Turnover
03/31/22 - 1.85
12/31/21 - 0.00
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©